Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Histone deacetylase (HDAC) inhibitor up-regulates car expression and targeted antigen intensity, increasing antitumor efficacy

Histone deacetylase (HDAC) inhibitor up-regulates car expression and targeted antigen intensity, increasing antitumor efficacy

US Patent 11547740 · Granted Jan 10, 2023

Estimated economic value: $6,320,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Generation of CTL lines with specificity against multiple tumor antigens or mult2025
Reprogramming CD4 t cells into cytotoxic CD8 cells by forced expression of CD8ab2025
Pepmixes to generate multiviral CTLs with broad specificity2025
Pepmixes to generate multiviral CTLS with broad specificity2024
Immunogenic antigen identification from a pathogen and correlation to clinical e2024
Oncolytic virotherapy with helper-dependent adenoviral-based vectors expressing 2024
Compositions and methods for the treatment of HER2-expressing solid tumors2022
Methods for inducing selective apoptosis2021
CD5 chimeric antigen receptor for adoptive T cell therapy2020
Oncolytic virotherapy and immunotherapy2020
Generation of CTL lines with specificity against multiple tumor antigens or mult2019
Histone deacetylase (HDAC) inhibitor up-regulates car expression and targeted an2019